Projects per year
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
Optimization of Prostate-Specific Membrane Antigen-Targeted Radiation
Tagawa, S. T. (PI), Bander, N. H. (CoPI), Vallabhajosula, S. (CoPI), Babich, J. J. (CoPI), Ballman, K. V. (CoPI), Beltran, H. (CoPI), Jhanwar, Y. Y. (CoPI), Khani, F. (CoPI), Sartor, A. (CoPI), Harshman, L. C. (CoPI), Czernin, J. J. (CoPI) & Gnjatic, S. (CoPI)
1/1/17 → …
Project: Research project
-
PLANNING GRANT FOR LSUMC STANLEY S SCOTT CANCER CENTER
Sartor, A. (PI) & Correa, P. (CoPI)
7/1/95 → 6/30/00
Project: Research project
-
[177Lu] Lu-PSMA-617 treatment for metastatic castration-resistant prostate cancer (mCRPC) with cerebral and cerebellar metastases
Belge Bilgin, G., Bilgin, C., Burkett, B. J., Thorpe, M. P., Packard, A. T., Fidanli, F., Childs, D. S., Muniz, M., Orme, J. J., Quevedo, J. F., Kizilbash, S. H., Kwon, E. D., Johnson, G. B., Johnson, D. R., Sartor, O. & Kendi, A. T., 2025, (Accepted/In press) In: European Journal of Nuclear Medicine and Molecular Imaging.Research output: Contribution to journal › Article › peer-review
-
177Lu-PSMA-617 Monotherapy Is Provocative but No Standard of Care for Metastatic Hormone-Sensitive Prostate Cancer
Hadaschik, B., Gillessen, S. & Sartor, O., Nov 3 2025, In: Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 66, 11, p. 1688-1689 2 p.Research output: Contribution to journal › Article › peer-review
-
Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE study: Clinical Studies
O’Sullivan, J. M., Heinrich, D., Castro, E., George, S., Dizdarevic, S., Baldari, S., Essler, M., Jong, I. J. D., Lastoria, S., Hammerer, P. G., Tombal, B., James, N. D., Meltzer, J., Sandström, P. & Sartor, O., Mar 9 2025, In: British journal of cancer. 132, 4, p. 354-360 7 p., 101993.Research output: Contribution to journal › Article › peer-review
Open Access -
Corrigendum to “Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial” [Eur. Urol. 86 (2024) 552–562, (S0302283824025600), (10.1016/j.eururo.2024.08.021)]
Armstrong, A. J., Sartor, O., de Bono, J., Chi, K., Fizazi, K., Krause, B. J., Herrmann, K., Rahbar, K., Tagawa, S. T., Saad, F., Beer, T. M., Wu, J., Mirante, O. & Morris, M. J., Jun 2025, In: European urology. 87, 6, p. 738-739 2 p.Research output: Contribution to journal › Comment/debate › peer-review
-
Current and future directions in theranostics for neuroendocrine prostate cancer
Belge Bilgin, G., Lucien-Matteoni, F., Chaudhuri, A. A., Orme, J. J., Childs, D. S., Muniz, M., Li, G. G., Chauhan, P. S., Lee, S. B., Gupta, S., Thorpe, M. P., Johnson, D. R., Johnson, G. B., Kendi, A. T. & Sartor, O., May 2025, In: Cancer Treatment Reviews. 136, 102941.Research output: Contribution to journal › Review article › peer-review